FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
FirstFT: Apple picks next CEO
Bank of England will only raise rates amid a severe supply shortage
Indonesia’s geophysics agency reports a magnitude 6 quake off Timor Island, with no tsunami...
Jim Cramer Says 'This Is Not A Circular Deal' As Amazon, Anthropic Lock In Massive $100 Billion AI Pact: 'Isn't It Possible That Everyone Wins?'
Trump says efforts to extract nuclear “dust” from Iran will take significant time and be...
U.S. and Iran Engage in Heightened Rhetoric Amid Stalled Peace Talks
JPMorgan’s national security initiative to expand in Europe
Exclusive-SpaceX tries to woo Wall Street with three-day analyst meeting this week, sources say
Iran alleges US struck Iranian commercial vessel, demands crew be released – Foreign...
Kevin Warsh Heads for the Hill: A Confirmation Hearing Guide
It Doesn’t Matter What Kevin Warsh Has to Say
EQT Raises $15.6B for Asia Private Equity Fund
Quilter plc sees JPMorgan reduce its price target to 206p from 212p....
Congo to Halt Cash Dollar Use Next Year to Prop Local Unit
Costco Increases Quarterly Dividend by 13%
AI Stocks Expected to Lead Nasdaq Recovery
Microsoft and Meta Prepare for Earnings Reports Amid AI Competition
IBM Set to Release Earnings Report This Wednesday
Fitch Reports Easing of China's Shadow Lending Practices
South Korea Issues 20-Year Government Bonds at 3.610% Yield
New Zealand’s RBNZ sectoral factor model shows inflation at +2.7% YoY in Q1....
Global clean power growth points to permanent shift, analysts say
The big short meets private credit
EQT and Omers to lift funding for struggling broadband group to €5bn
Seoul shares hit record intraday high on back of tech sector rally-NA...
Toby Neugebauer Incredibly Bullish on Project Matador and Calls for Sale of Company to Maximize Shareholder Value
Trump Comments on Challenges of Extracting Nuclear Material in Iran
Renewable Energy Surpasses Global Electricity Demand in 2022
South Korea issues 20-year government bonds at a yield of 3.610%, according to the finance...
Badr Jafar: Private sector must shoulder stability in times of war
Tesla Settles Last-Minute Over Fatal 2018 Model S Crash That Killed Florida Teen
Sanrio Launches Gaming Brand, Tapping Fast-Growing Market
WTI edges higher to near $86.00 on uncertainty over US-Iran talks-FX...
Asia stocks mixed amid Iran uncertainty; KOSPI hits record high on AI rally
China’s youth jobless rate rises to 16.9% in March
South Korean Battery Stocks Rally on Mercedes-Benz Partnership
Indonesia’s equity benchmark edges down 0.5% to 7,550 points at the open....
Three Ships Including an Iranian Vessel Attempt Hormuz Transits
US-Iran Talks Set for Islamabad as Ceasefire Deadline Approaches
Coinbase Faces Legal Challenges Amid Board Restructuring
AST SpaceMobile Faces $2 Billion Market Cap Loss After Satellite Deployment Issue
Lululemon to Open Eight New Stores in Mexico as Part of North American Expansion
Cadence Design Systems Stock Rises Amid Geopolitical Concerns
Snowflake's Fair Value Estimate Reduced Amid AI Growth
Indonesia Exchange Chief Reports MSCI Acknowledgment of Proposals
Japan's Finance Minister Addresses Market Volatility
Middle East crisis: ‘Highly unlikely’ Iran ceasefire will be extended if no deal reached, Trump says
Indonesia exchange chief says MSCI has acknowledged its four proposals, which is...
Indonesia exchange chief says dialogue with global investors continues to strengthen the capital...
EQT Life Sciences Sells Stake in Tubulis to Gilead Sciences for Up to $5 Billion
EQT Life Sciences has completed the sale of its minority stake in Tubulis, a clinical-stage biotechnology company based in Germany. The transaction involves Gilead Sciences, a prominent player in the biopharmaceutical industry, acquiring the stake for a total consideration of up to $5 billion.
Tubulis specializes in the development of next-generation antibody-drug conjugates (ADCs), which are designed to improve the efficacy and safety of cancer treatments. This strategic move by EQT Life Sciences marks a significant exit from its investment in Tubulis, reflecting the growing interest in innovative cancer therapies.
The sale to Gilead Sciences is expected to enhance the latter's portfolio in the oncology space, aligning with its commitment to advancing therapeutic options for patients.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News